Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
#199 most reported symptom for this vaccine
Nasal congestion has been reported 137 times in association with Tdap (Boostrix) vaccination in VAERS. This represents 0.3% of all 52,846 reports for this vaccine.
Among these reports, 1 mentioned death (0.73%) and 15 involved hospitalization (10.9%).
Nasal congestion is the #199 most frequently reported symptom for Tdap (Boostrix) out of 2243 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
Seeing 137 reports of Nasal congestion after Tdap (Boostrix) vaccination may seem alarming, but context is critical.
The mortality rate among these reports is very low at 0.73%, suggesting most cases are non-fatal.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.